Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 3/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676940 | 1.00 | PAK4 (0.34) | PAK4PAK1HRH4RETIGF1R | |
| SCHEMBL3764358 | 0.80 | — | — | |
| SCHEMBL3643662 | 0.76 | MAP3K12 (0.40) | — | |
| SCHEMBL3643663 | 0.76 | MAP3K12 (0.40) | — | |
| SCHEMBL3638839 | 0.75 | CHRM3 (0.41) | HRH4CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL3638836 | 0.75 | CHRM3 (0.41) | HRH4CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL3673996 | 0.74 | AURKA (0.46) | PAK4PAK1RETIGF1R | |
| SCHEMBL3673997 | 0.74 | AURKA (0.46) | PAK4PAK1RETIGF1R | |
| SCHEMBL3670127 | 0.71 | GRM4 (0.37) | PAK4PAK1GRM4 | |
| SCHEMBL3670128 | 0.71 | GRM4 (0.37) | PAK4PAK1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060013-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2164842-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008147626-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060013-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | PAK4 237/4885PAK1 74/4885HRH4 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.